Novartis’ BAF312 meets main goal in secondary progressive multiple sclerosis trial

A phase III study, assessing the efficacy and safety of Novartis’ BAF312 (siponimod) in secondary progressive multiple sclerosis (SPMS), met its primary endpoint of a reduction in the risk of disability progression, versus placebo. http://clinicaltrials.pharmaceutical-business-review.com/news/novartis-baf312-meets-main-goal-in-secondary-progressive-multiple-sclerosis-trial-250816-4988439